Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon van der Pol

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|July 15, 2021
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic ReviewSimon van der Pol, Paula Rojas Garcia, Maarten J Postma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in PracticeTanja Fens, Simon van der Pol, Janwillem W H Kocks, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2021
The tripartite insurance model (TIM): a financial incentive to prevent outbreaks of infections due to multidrug-resistant microorganisms in hospitalsSimon van der Pol, Jan-Willem H Dik, Corinna Glasner, et al.
Pharmacoeconomics|November 1, 2021
Health-Economic Analyses of Diagnostics: Guidance on Design and ReportingSimon van der Pol, Paula Rojas Garcia, Fernando Antoñanzas Villar, et al.
Vaccine|September 28, 2025
Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the NetherlandsFlorian Zeevat, Jos Luttjeboer, Koos Korsten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency FrontierSimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Journal of Market Access & Health Policy|December 14, 2020
The impact of patent expiry on drug prices: insights from the Dutch marketSimon van der Schans, Gert T Vondeling, Qi Cao, et al.
Journal of Critical Care|April 7, 2024
The value of artificial intelligence for the treatment of mechanically ventilated intensive care unit patients: An early health technology assessmentLeslie R Zwerwer, Simon van der Pol, Kai Zacharowski, et al.
Health Economics Review|January 16, 2024
Mechanical ventilation as a major driver of COVID-19 hospitalization costs: a costing study in a German settingLeslie R Zwerwer, Jan Kloka, Simon van der Pol, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|January 17, 2019
Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefitsSimon van der Pol, Maartje S Jacobs, Karina Meijer, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|July 15, 2021
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic ReviewSimon van der Pol, Paula Rojas Garcia, Maarten J Postma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in PracticeTanja Fens, Simon van der Pol, Janwillem W H Kocks, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2021
The tripartite insurance model (TIM): a financial incentive to prevent outbreaks of infections due to multidrug-resistant microorganisms in hospitalsSimon van der Pol, Jan-Willem H Dik, Corinna Glasner, et al.
Pharmacoeconomics|November 1, 2021
Health-Economic Analyses of Diagnostics: Guidance on Design and ReportingSimon van der Pol, Paula Rojas Garcia, Fernando Antoñanzas Villar, et al.
Vaccine|September 28, 2025
Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the NetherlandsFlorian Zeevat, Jos Luttjeboer, Koos Korsten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency FrontierSimon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Journal of Market Access & Health Policy|December 14, 2020
The impact of patent expiry on drug prices: insights from the Dutch marketSimon van der Schans, Gert T Vondeling, Qi Cao, et al.
Journal of Critical Care|April 7, 2024
The value of artificial intelligence for the treatment of mechanically ventilated intensive care unit patients: An early health technology assessmentLeslie R Zwerwer, Simon van der Pol, Kai Zacharowski, et al.
Health Economics Review|January 16, 2024
Mechanical ventilation as a major driver of COVID-19 hospitalization costs: a costing study in a German settingLeslie R Zwerwer, Jan Kloka, Simon van der Pol, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|January 17, 2019
Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefitsSimon van der Pol, Maartje S Jacobs, Karina Meijer, et al.
Pageof 3